Announced Tue, 26 May · 20:43 IST

Standalone Audited Financial Results For Quarter And Year Ended March 31, 2026 and reappointment of P Vishnu Adithan as Internal Auditor of the Company

Pat Growth 25pctEbitda Margin CompressionResults View source PDF

LOTUSEYE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.7%1-day move
₹110.85
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.7-2.6-1.2+1.0-0.8+5.6+20.2+9.6+7.2
Up moveDown movePending
AI summary

Lotus Eye Hospital reported standalone audited FY2026 results with total income of Rs 5,489.03 lakhs, up 7.9% from Rs 5,086.38 lakhs in FY2025. Revenue from operations grew 8.4% year-on-year to Rs 5,371.41 lakhs. Net profit after tax stood at Rs 73.93 lakhs, a 25.4% increase from Rs 58.97 lakhs in the prior year. The company posted a Q4 loss of Rs 37.51 lakhs, dragged down by higher service and employee costs in the quarter. Statutory auditors issued an unmodified (clean) opinion with no qualifications. The Board also reappointed P Vishnu Adithan as Internal Auditor for FY2026-27. Total assets grew to Rs 8,259.74 lakhs from Rs 6,957.37 lakhs, primarily due to a significant increase in property, plant and equipment (Rs 5,918.30 lakhs vs Rs 4,874.18 lakhs).

Likely market impact

The 25.4% PAT growth is a positive signal for shareholders, though the EBITDA margin compression (from ~14.4% to ~9.4%) and heavy capex spending (Rs 1,295 lakhs in investing activities) raise concerns about profitability sustainability. The clean audit opinion removes any qualification-related risk.